Mucosal leishmaniasis . Current scenario and prospects for treatment.

摘要: Leishmaniasis causes significant morbidity and mortality thus constitutes a serious public health problem. Even though it has long been endemic in developing countries, recent years the economic globalization increased volume of international travel have extended its prevalence developed countries. In addition, native populations may be exposed to infection through blood transfusion use products produced from infected asymptomatic individuals. Mucosal leishmaniasis (ML) is chronic form this infection, which attacks mucosa. most cases results metastatic spread Leishmania (Viannia) braziliensis cutaneous lesions. It healthcare issue because wide demographic distribution, association with levels, pressing concern that tourists who areas might present disease even later. The treatment currently available for ML based on drugs such as pentavalent antimony-containing compounds, amphotericin B deoxycholate pentamidine often guarantees satisfactory clinical response. Nevertheless, also frequently provokes side effects. This review offers critical analysis now future prospects disease.